BioSpace / Business Wire · Jun 2026
FDA granted Orphan Drug and Rare Pediatric Disease designations to GEn-1123 for Duchenne muscular dystrophy, a regulatory milestone that supports the company’s rare-disease program.
AI platform accelerating therapies for rare & inflammatory diseases.
Company research
Public company, workplace, funding, and market signals
Overview
GEn1E Lifesciences is a clinical-stage, Phase 2 biotech developing AI-guided precision immunomodulators for inflammatory and rare diseases. Its lead asset is GEn-1124, a p38α:MK2 dual signal modulator for ARDS; the company also pursues GEn-1123 for rare chronic indications and an ERK 1/2 program. Public sources vary on the founding year (2018 on the company site/Y Combinator vs. 2019 on LinkedIn), so 2018 is used here.
Primary product
GEn-1124, a p38α:MK2 dual signal modulator for acute respiratory distress syndrome (ARDS) and other inflammatory indications
Founded
2018
Headquarters
Palo Alto, California, USA
Team size
10-20
Industry
Biotechnology Research
Sub-industry
Clinical-stage AI-enabled drug discovery and immunomodulatory therapeutics
Offices
Open Positions
0 jobs at GEn1E Lifesciences
No open positions
Check back later for new openings